Pierluigi Paracchi, co-founder and chief executive of Genenta Science srl, is one of two winners of the Lyfebulb-Helsinn Innovation award in oncology for work in discovering and developing cancer therapies with a potential for commercialisation. The award is for entrepreneurs who have either been cancer patients, or have had a close relative affected by the disease. Mr Paracchi is an experienced venture capitalist who co-founded Genenta in 2014 to develop new immunotherapies for cancer. The company’s technology platform is based on gene transfer, enabling the delivery of immunomodulatory molecules to the tumour microenvironment.
The other recipient of the award is Mihir Shah, co-founder of UE LifeSciences Inc.
Helsinn announced the awards on 19 March 2019
Copyright 2019 Evernow Publishing Ltd